JNJ

Johnson & Johnson (JNJ) | Rumor.io

Johnson & Johnson

JNJ

Attention (50-day avg)0.02%

Attention rank (50-day avg)#266

Bullish sentiment (50-day avg)89%

Price to earnings ratio31.7

Market capitalization655.4B

Earnings per share8.62

Dividend yield (TTM)1.97%

Revenue (annual)94.2B

Net income (annual)26.8B

Social

What share of all stock conversation is about JNJ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.06	0.02% +0.01	0.02% +0.01	0.02% -0.03

Sep 29

Johnson & Johnson has increased its dividend for 63 consecutive years, paying $5.20 per share annually.
IMAAVY (nipocalimab-aahu) has shown sustained disease control and improved daily functioning in patients with generalized myasthenia gravis, according to new clinical data from the Phase 3 Vivacity-MG3 program.
Analysts at BofA have raised the price target for Johnson & Johnson to $278 from $263, citing increased peak sales estimates for Icotyde, a new pill for psoriasis.

Generated by AI

Sentiment

Of the messages about JNJ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	94.46% +1.13	95.02% +7.87	83.39% -6.85
Bearish	0% 0	5.54% -1.13	4.98% -7.87	16.61% +6.85

Bullish· Sep 2

Johnson & Johnson's stock has hit new 52-week highs, demonstrating its strong performance.
The company has consistently delivered big profits, with those who played the stock potentially seeing a 50% increase in value.
Johnson & Johnson has a history of steady growth, with a 1-year dividend growth rate of 4.38% and a 63-year consecutive streak of increasing its dividend.

Bearish· Jun 4

$JNJ is at a make-or-break point on the daily chart, hugging a key diagonal trendline, and could slide to the 200-day moving average around $210 if it breaks.
The company's daily chart is flirting with a breakdown, which could lead to a drop to the 200 DMA around $210.
Net put premiums have jumped, especially for the 8/21 and 10/16 options, indicating a high likelihood of a breakdown in the stock.

Generated by AI

Topics

Of the messages about JNJ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	—	1.44%	10.03%	54.1%
Technical Analysis	—	4.68%	6.58%	4.72%
Announcements	—	74.1%	61.46%	8.97%
Earnings	—	0%	7.24%	5.14%
Controversies	—	10.43%	3.26%	2.3%
Analysts	—	9.35%	11.43%	24.77%

Earnings· Apr 14

Johnson & Johnson reported Q1 2026 earnings, beating EPS estimates by $0.02 and revenue estimates, with EPS of $2.70 and revenue of $24.06B.
The company raised its FY26 adjusted EPS view to $11.45-$11.65 and its FY26 estimated reported revenue view to $100.3B-$101.3B.
Johnson & Johnson also increased its quarterly dividend by 3.1% to $1.34 per share, marking the 64th year of consecutive increases.

Analysts· Apr 17

Analysts are cautious about JNJ's future dividend increases, with one suggesting lower increases may be necessary to maintain a strong total shareholder return.
The recent regain of rights to XLRP gene therapy by MeiraGTx may streamline JNJ's pipeline focus and remove a clinical uncertainty, potentially lifting a regulatory overhang on the stock.
One analyst recommends focusing on business fundamentals and total shareholder return, rather than just dividend increases, when evaluating JNJ's performance.

Announcements· Jun 11

Johnson & Johnson has entered precision medical device manufacturing via a $250K order for a custom laser drilling system from CMS Laser.
Johnson & Johnson's nipocalimab has hit the primary endpoint in a Phase 2/3 trial for warm autoimmune hemolytic anemia, with durable hemoglobin response from Week 1.
Johnson & Johnson's nipocalimab has received FDA Priority Review, with no approved therapies in the indication, and has shown statistically significant durable hemoglobin response in a Phase 2/3 trial.

Controversies· Dec 23

A Baltimore jury ordered Johnson & Johnson to pay $1.56 billion in a talc mesothelioma case, citing failure to warn about asbestos in baby powder.
The verdict includes $60 million in compensatory damages and $1.5 billion in punitive damages, with Johnson & Johnson planning to appeal.
The company faces over 60,000 pending cases related to talc products, raising concerns about the impact of legal risks on the company's liability profile.

Macro· Apr 20

The post discusses the biotech sector and the recent surges in psychedelic stocks, specifically CMPS, driven by positive Phase 3 trial data and analyst revisions.
The author highlights the competitive advantage of CMPS over Johnson & Johnson's Spravato, citing its rapid and lasting benefits from minimal doses.
The post mentions growing institutional interest in CMPS, fueled by political support for psychedelic research, which is contributing to its momentum in the market.

Technical Analysis· Jun 4

$JNJ is at a make-or-break point on its daily chart, sitting right on a key diagonal trendline, and a confirmed move could send it sliding to the 200 DMA around $210.
The company has been flirting with a breakdown for 3 days, and a confirmed move lower could send it down to the 200-day moving average around $210.
Net put premiums have jumped on Wednesday, especially for the 8/21 and 10/16 expirations, indicating a potential increase in bearish sentiment.

Generated by AI

Community

Of the messages about JNJ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	47.83%	46.6%	49.39%	55.14%
Newcomers	52.17%	53.4%	50.61%	44.86%

Regulars· Sep 23

The regulars are discussing the strong long-term survival signal for TECVAYLI and DARZALEX FASPRO in patients with multiple myeloma, with a 36-month overall survival rate of 83.3% compared to 65.0% with standard of care.
Johnson & Johnson's Q3 earnings are expected to be $2.85 EPS, with a report date of October 13.
The quality momentum scanner has identified JNJ as the second strongest stock in the Pharma sector, with a score of 16.

Newcomers· Sep 25

Newcomers are considering Johnson & Johnson (JNJ) as a potential long-term value/dividend play, citing its potential for long-term growth and steady dividends.
Some newcomers are warning that JNJ may be overvalued, given its recent run-up and the potential for pharmaceutical growth, margins, and litigation costs to impact the company's performance.
Technical analysis suggests that JNJ has completed a bullish Gartley pattern, with some traders calling for a potential target price and tracking their calls for accuracy.

Generated by AI

Johnson & Johnson (NYSE:JNJ) reported new long term IMAAVY data in generalized myasthenia gravis, including adolescent outcomes. The company said adolescents with gMG on IMAAVY showed sustained disease control and reduced reliance on corticosteroids, with no new safety signals. Survey findings from healthcare professionals indicated IMAAVY may address unmet needs for more consistent symptom management in gMG treatment. The new IMAAVY findings in adolescent gMG sit alongside broader shifts...

10h agoYahoo Finance

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $267.66, marking a -1.58% move from the previous day.

14h agoYahoo Finance

Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss - Johnson & Johnson (NYSE:JNJ

Analysts expect Johnson & Johnson's Q3 FY2027 sales to be in line, but EPS to be below consensus due to IPR&D dilution.

18h agobenzinga.com

Johnson & Johnson: Strong Catalysts, But I’m Staying At Hold (NYSE:JNJ)

Johnson & Johnson reports Q3 earnings Oct 13. Explore key growth drivers in oncology & Tremfya, plus valuation risks with a premium P/E. Click for this JNJ update.

22h agoSeeking Alpha

Johnson & Johnson's Q3 2026 Earnings: What to Expect

22h agoBarchart.com

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

23h agoYahoo Finance

Also Discussed

Investors talking about JNJ also mention

#	Name	Attention
1	The Procter & Gamble CompanyPG	0.01%+0.01
2	AbbVie Inc.ABBV	0.03%-0.03
3	Pfizer Inc.PFE	0.04%-0.01
4	Merck & Co., Inc.MRK	0.01%-0.06
5	Kenvue Inc.KVUE	0%0
6	3M CompanyMMM	0%new
7	Bristol-Myers Squibb CompanyBMY	0.01%0
8	The Coca-Cola CompanyKO	0.02%+0.02
9	Verizon Communications Inc.VZ	0.26%+0.25
10	Amgen Inc.AMGN	0.01%+0

Johnson & Johnson

Healthcare
Drug Manufacturers - General

Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular care, while its MedTech segment provides medical devices and solutions used in surgery, orthopedics, interventional procedures, and vision care. The company serves hospitals, clinicians, patients, and healthcare systems in markets around the world, making it a central participant in both drug development and medical device supply chains. Johnson & Johnson is known for operating at the intersection of large-scale research, clinical innovation, and essential healthcare delivery, with products that support prevention, treatment, diagnosis, and recovery across a wide range of medical settings.

Website

Location

One Johnson & Johnson Plaza

New Brunswick, NJ, 08933

United States

Social

What share of all stock conversation is about JNJ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.06	0.02% +0.01	0.02% +0.01	0.02% -0.03

Sep 29

Johnson & Johnson has increased its dividend for 63 consecutive years, paying $5.20 per share annually.
IMAAVY (nipocalimab-aahu) has shown sustained disease control and improved daily functioning in patients with generalized myasthenia gravis, according to new clinical data from the Phase 3 Vivacity-MG3 program.
Analysts at BofA have raised the price target for Johnson & Johnson to $278 from $263, citing increased peak sales estimates for Icotyde, a new pill for psoriasis.

Generated by AI

Sentiment

Of the messages about JNJ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	94.46% +1.13	95.02% +7.87	83.39% -6.85
Bearish	0% 0	5.54% -1.13	4.98% -7.87	16.61% +6.85

Bullish· Sep 2

Johnson & Johnson's stock has hit new 52-week highs, demonstrating its strong performance.
The company has consistently delivered big profits, with those who played the stock potentially seeing a 50% increase in value.
Johnson & Johnson has a history of steady growth, with a 1-year dividend growth rate of 4.38% and a 63-year consecutive streak of increasing its dividend.

Bearish· Jun 4

$JNJ is at a make-or-break point on the daily chart, hugging a key diagonal trendline, and could slide to the 200-day moving average around $210 if it breaks.
The company's daily chart is flirting with a breakdown, which could lead to a drop to the 200 DMA around $210.
Net put premiums have jumped, especially for the 8/21 and 10/16 options, indicating a high likelihood of a breakdown in the stock.

Generated by AI

Topics

Of the messages about JNJ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	—	1.44%	10.03%	54.1%
Technical Analysis	—	4.68%	6.58%	4.72%
Announcements	—	74.1%	61.46%	8.97%
Earnings	—	0%	7.24%	5.14%
Controversies	—	10.43%	3.26%	2.3%
Analysts	—	9.35%	11.43%	24.77%

Earnings· Apr 14

Johnson & Johnson reported Q1 2026 earnings, beating EPS estimates by $0.02 and revenue estimates, with EPS of $2.70 and revenue of $24.06B.
The company raised its FY26 adjusted EPS view to $11.45-$11.65 and its FY26 estimated reported revenue view to $100.3B-$101.3B.
Johnson & Johnson also increased its quarterly dividend by 3.1% to $1.34 per share, marking the 64th year of consecutive increases.

Analysts· Apr 17

Analysts are cautious about JNJ's future dividend increases, with one suggesting lower increases may be necessary to maintain a strong total shareholder return.
The recent regain of rights to XLRP gene therapy by MeiraGTx may streamline JNJ's pipeline focus and remove a clinical uncertainty, potentially lifting a regulatory overhang on the stock.
One analyst recommends focusing on business fundamentals and total shareholder return, rather than just dividend increases, when evaluating JNJ's performance.

Announcements· Jun 11

Johnson & Johnson has entered precision medical device manufacturing via a $250K order for a custom laser drilling system from CMS Laser.
Johnson & Johnson's nipocalimab has hit the primary endpoint in a Phase 2/3 trial for warm autoimmune hemolytic anemia, with durable hemoglobin response from Week 1.
Johnson & Johnson's nipocalimab has received FDA Priority Review, with no approved therapies in the indication, and has shown statistically significant durable hemoglobin response in a Phase 2/3 trial.

Controversies· Dec 23

A Baltimore jury ordered Johnson & Johnson to pay $1.56 billion in a talc mesothelioma case, citing failure to warn about asbestos in baby powder.
The verdict includes $60 million in compensatory damages and $1.5 billion in punitive damages, with Johnson & Johnson planning to appeal.
The company faces over 60,000 pending cases related to talc products, raising concerns about the impact of legal risks on the company's liability profile.

Macro· Apr 20

The post discusses the biotech sector and the recent surges in psychedelic stocks, specifically CMPS, driven by positive Phase 3 trial data and analyst revisions.
The author highlights the competitive advantage of CMPS over Johnson & Johnson's Spravato, citing its rapid and lasting benefits from minimal doses.
The post mentions growing institutional interest in CMPS, fueled by political support for psychedelic research, which is contributing to its momentum in the market.

Technical Analysis· Jun 4

$JNJ is at a make-or-break point on its daily chart, sitting right on a key diagonal trendline, and a confirmed move could send it sliding to the 200 DMA around $210.
The company has been flirting with a breakdown for 3 days, and a confirmed move lower could send it down to the 200-day moving average around $210.
Net put premiums have jumped on Wednesday, especially for the 8/21 and 10/16 expirations, indicating a potential increase in bearish sentiment.

Generated by AI

Community

Of the messages about JNJ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	47.83%	46.6%	49.39%	55.14%
Newcomers	52.17%	53.4%	50.61%	44.86%

Regulars· Sep 23

The regulars are discussing the strong long-term survival signal for TECVAYLI and DARZALEX FASPRO in patients with multiple myeloma, with a 36-month overall survival rate of 83.3% compared to 65.0% with standard of care.
Johnson & Johnson's Q3 earnings are expected to be $2.85 EPS, with a report date of October 13.
The quality momentum scanner has identified JNJ as the second strongest stock in the Pharma sector, with a score of 16.

Newcomers· Sep 25

Newcomers are considering Johnson & Johnson (JNJ) as a potential long-term value/dividend play, citing its potential for long-term growth and steady dividends.
Some newcomers are warning that JNJ may be overvalued, given its recent run-up and the potential for pharmaceutical growth, margins, and litigation costs to impact the company's performance.
Technical analysis suggests that JNJ has completed a bullish Gartley pattern, with some traders calling for a potential target price and tracking their calls for accuracy.

Generated by AI

Johnson & Johnson

Social

Sep 29

Bullish· Sep 2

Bearish· Jun 4

Earnings· Apr 14

Analysts· Apr 17

Announcements· Jun 11

Controversies· Dec 23

Macro· Apr 20

Technical Analysis· Jun 4

Regulars· Sep 23

Newcomers· Sep 25

Johnson & Johnson (JNJ) Shares In Focus After New Adolescent gMG Data

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss - Johnson & Johnson (NYSE:JNJ

Johnson & Johnson: Strong Catalysts, But I’m Staying At Hold (NYSE:JNJ)

Johnson & Johnson's Q3 2026 Earnings: What to Expect

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Also Discussed

Johnson & Johnson

Company Information

Location

Johnson & Johnson (JNJ) Shares In Focus After New Adolescent gMG Data

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss - Johnson & Johnson (NYSE:JNJ

Johnson & Johnson: Strong Catalysts, But I’m Staying At Hold (NYSE:JNJ)

Johnson & Johnson's Q3 2026 Earnings: What to Expect

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Also Discussed

Social

Sep 29

Bullish· Sep 2

Bearish· Jun 4

Earnings· Apr 14

Analysts· Apr 17

Announcements· Jun 11

Controversies· Dec 23

Macro· Apr 20

Technical Analysis· Jun 4

Regulars· Sep 23

Newcomers· Sep 25